Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer
Authors:
Open Access
- 28 May 2020
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 26 (20) , 2657-2668
Abstract
BACKGROUND The management of rectal cancer patients is mainly based on the use of the magnetic resonance imaging (MRI) technique as a diagnostic tool for both staging and restaging. After treatment, to date, the evaluation of complete response is based on the histopathology assessment by using different tumor regression grade (TRG) features (e.g., Dworak or Mandard classifications). While from the radiological point of view, the main attention for the prediction of a complete response after chemotherapy treatment focuses on MRI and the potential role of diffusion-weighted images and perfusion imaging represented by dynamic-contrast enhanced MRI. The main aim is to find a reliable tool to predict tumor response in comparison to histopathologic findings. AIM To investigate the value of dynamic contrast-enhanced perfusion-MRI parameters in the evaluation of the healthy rectal wall and tumor response to chemo-radiation therapy in patients with local advanced rectal cancer with histopathologic correlation. METHODS Twenty-eight patients with biopsy-proven rectal adenocarcinoma who underwent a dynamic contrast-enhanced MR study performed on a 1.5T MRI system (Achieva, Philips), before (MR1) and after chemoradiation therapy (MR2), were enrolled in this study. The protocol included T1 gadolinium enhanced THRIVE sequences acquired on axial planes. A dedicated workstation was used to generate color permeability maps. Region of interest was manually drawn on tumor tissue and normal rectal wall, hence the following parameters were calculated and statistically analyzed: Relative arterial enhancement (RAE), relative venous enhancement (RVE), relative late enhancement (RLE), maximum enhancement (ME), time to peak and area under the curve (AUC). Perfusion parameters were related to pathologic TRG (Mandard's criteria; TRG1 = complete regression, TRG5 = no regression). RESULTS Ten tumors (36%) showed complete or subtotal regression (TRG1-2) at histology and classified as responders; 18 tumors (64%) were classified as non-responders (TRG3-5). Perfusion MRI parameters were significantly higher in the tumor tissue than in the healthy tissue in MR1 (P < 0.05). At baseline (MR1), no significant difference in perfusion parameters was found between responders and non-responders. After chemo-radiation therapy, at MR2, responders showed significantly (P < 0.05) lower perfusion values [RAE (%) 54 +/- 20; RVE (%) 73 +/- 24; RLE (%): 82 +/- 29; ME (%): 904 +/- 429] compared to non-responders [RAE (%): 129 +/- 45; RVE (%): 154 +/- 39; RLE (%): 164 +/- 35; ME (%): 1714 +/- 427]. Moreover, in responders group perfusion values decreased significantly at MR2 [RAE (%): 54 +/- 20; RVE (%): 73 +/- 24; RLE (%): 82 +/- 29; ME (%): 904 +/- 429] compared to the corresponding perfusion values at MR1 [RAE (%): 115 +/- 21; RVE (%): 119 +/- 21; RLE (%): 111 +/- 74; ME (%): 1060 +/- 325]; (P < 0.05). Concerning the time-intensity curves, the AUC at MR2 showed significant difference (P = 0.03) between responders and non-responders [AUC (mm(2) x 10(-3)) 121 +/- 50 vs 258 +/- 86], with lower AUC values of the tumor tissue in responders compared to non-responders. In non-responders, there were no significant differences between perfusion values at MR1 and MR2. CONCLUSION Dynamic contrast perfusion-MRI analysis represents a complementary diagnostic tool for identifying vascularity characteristics of tumor tissue in local advanced rectal cancer, useful in the assessment of treatment response.Keywords
This publication has 27 references indexed in Scilit:
- Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry studyThe Lancet, 2018
- Value of DCE-MRI for staging and response evaluation in rectal cancer: A systematic reviewEuropean Journal of Radiology, 2017
- Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Correlation between quantitative and semiquantitative parameters in DCE-MRI with a blood pool agent in rectal cancer: can semiquantitative parameters be used as a surrogate for quantitative parameters?Abdominal Radiology, 2017
- Locally advanced rectal cancer: Qualitative and quantitative evaluation of diffusion-weighted MR imaging in the response assessment after neoadjuvant chemo-radiotherapyEuropean Journal of Radiology Open, 2016
- Recent developments in colorectal imagingCurrent Opinion in Gastroenterology, 2015
- Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meetingEuropean Radiology, 2013
- Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant TreatmentFrontiers in Oncology, 2013
- Histopathology of Colorectal Cancer after Neoadjuvant Chemoradiation TherapyThe Open Pathology Journal, 2009
- Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlationsCancer, 1994